Rich Pharmaceuticals Inc. (fka RCHA)

[buythebuy]

RCHA Rich Pharmaceuticals' Division CannCodex Releases List of Conditional Use Permits Issued in California to Medicinal Cannabis Businesses
BEVERLY HILLS, CA--(NewMediaWire - May 9, 2017) - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in cutting edge healthcare and natural remedies, releases an initial list tracking all municipal cannabis licenses in World's Largest Cannabis market: California.

Newly released municipal licenses come in the form of Conditional Use Permits (CUP), which are now starting to be issued from various municipalities within California for the use in medicinal and recreational markets. These initial CUPs are highly sought after and extremely valuable because the state may require possession of one prior to being considered for state licensing in 2018.

Rich's newly launched CannCodex is now tracking all updates and releases of new cannabis licensing in California with an easy to use and free access on the web. This is a crucial part of the transition to a place that recognizes that cannabis possesses medicinal properties. To ensure an understanding of each city's regulations they have created a comprehensive list of cities issuing CUPs. The list will continue to be updated as they receive new information.

Marcus Laun, President of CannCodex, is delighted that CannCodex has launched with an effort to create an information product for the Cannabis Market in California. The CUP process is complicated and market participants are forced to execute a significant amount of research to get conversant. "We hope to support the thousands of market players with more clarity about the California market," he stated.

The list can be found at: www.canncodex.com

About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating AML, Hodgkin's Lymphoma and other blood related diseases. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. RP-323 is a phorbol ester, which induces differentiation and/or apoptosis in multiple cell lines and primary cells, activates protein kinase C (PKC), and modulates the activity of multiple downstream cell signaling pathways, including mitogen-activated protein kinase (MAPK) pathways. RP-323 induces PKC to produce NF kappa, which then produces NF kappa B that has the ability to regulate cellular responses by entering into the nucleus of cells. NF kappa B binds to DNA and changes the nature of the cell and (1) induces differentiation; (2) induces proliferation; (3) cytokine induction; (4) and/or apoptosis. Find out more at www.richpharmaceuticals.com